Profile: Pfizer Inc (PFE)
26 May 2017
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. As of December 31, 2016, the Company sold its products in over 125 countries.
The Company's IH brands include Prevnar 13, Xeljanz, Eliquis, Lyrica (the United States, Japan and certain other markets), Enbrel (outside the United States and Canada), Viagra (the United States and Canada), Ibrance, Xtandi and various over-the-counter (OTC) consumer products (Advil and Centrum). Its EH brands include Lipitor, Premarin family, Norvasc, Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries), Celebrex, Pristiq and various sterile injectable products. Its Internal Medicine products include Lyrica (outside all of Europe, Russia, Turkey, Israel and Central Asia countries), Viagra (United States and Canada), Chantix/Champix and Eliquis. Its vaccine products include Prevnar 13/Prevenar 13. Its oncology products include Ibrance, Sutent, Xalkori, Inlyta and Xtandi. Its inflammation and immunology products include Enbrel (outside the United States and Canada) and Xeljanz. Its rare diseases products include BeneFix, Genotropin, and Refacto AF/Xyntha.
The Company's categories and product lines in its consumer healthcare business include dietary supplements, such as Centrum brands (including Centrum, Centrum Silver, Centrum Men's and Women's, Centrum MultiGummies, Centrum VitaMints, Centrum Specialist, Centrum Flavor Burst and Centrum Kids), Caltrate and Emergen-C; pain management, such as Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Advil Menstrual Pain, Children's Advil, Infants' Advil and Advil Migraine) and ThermaCare; gastrointestinal, such as Nexium 24HR/Nexium Control and Preparation H, and respiratory and personal care, such as Robitussin, Advil Cold and Sinus, Advil Sinus Congestion and Pain, Dimetapp and ChapStick.
The Company's Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri- Loss of Exclusivity (LOE) Products), and Peri-LOE Products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio; Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the European Union (EU). Its Sterile Injectable Pharmaceuticals include generic injectables and specialty injectables (excluding Peri-LOE Products). Its Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as intravenous infusion products, including large volume intravenous solutions and their associated administration sets. As of December 31, 2016, the Company had 96 projects in clinical research and development.
The Company's Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the United States and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle East markets, and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East markets. Its Pfizer CentreOne includes revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to its manufacturing and supply agreements with Zoetis Inc., and revenues from legacy Hospira, Inc.'s One-2-One sterile injectables contract manufacturing operation.
235 E 42ND ST
NEW YORK NY 10017-5703
Company Web Links
- BRIEF-Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing
- BRIEF-FDA committee recommends approval of Pfizer's epoetin alfa biosimilar
- Drug approvals bounce back as R&D labs churn out new winners
- Exclusive - McConnell expects bipartisan support for bill reauthorising FDA user fees
- BRIEF-Pfizer recommends shareholders reject below-market mini-tender offer by TRC Capital